Sedation aripiprazole

The most common side effects associated with aripiprazole include headache, nausea, dyspepsia, agitation, anxiety, insomnia, somnolence, and akathisia. Dose-related adverse events include somnolence and akathisia. Early clinical experience indicates that akathisia may be avoided by starting the medication at doses lower than 10 mg and increasing the dose slowly. Aripiprazole is not associated with significant sedation, anticholinergic side effects, weight gain, or cardiovascular side effects (Petrie et al. 1997). 

A 27-year-old woman who took 330 mg of aripiprazole in a suicide attempt only suffered mild sedation despite a serum concentration of 716 jj.g/1, nearly six times the upper limit of the accepted target range (19). 

Atypical antipsychotics such as aripiprazole, olanzapine, que-tiapine, risperidone, and ziprasidone are effective as monotherapy or adjunctive therapy with lithium and valproate in the treatment of acute mania. Some antipsychotics have the potential to cause adverse effects such as extrapyramidal reactions, sedation, depression, emotional blunting, sexual dysfunction, weight gain, and orthostatic hypotension. Prophylactic use of antipsychotics may be needed for some patients with recurrent mania or mixed states, but the risks versus benefits must be weighed because of long-term adverse effects (e.g., obesity, type 2 diabetes, hyperlipidemia, hyperprolactinemia, cardiac disease, and tardive dyskinesia). ... 

Comparative stndies In six patients with Huntington s disease, in whom aripiprazole and tetrabenazine were compared, tetrabenazine caused more sedation sleepiness 15%... 

Antipsychotic drugs are more often used in the treatment of bipolar illness. Lithium was equivalent to aripiprazole, and both were superior to placebo, in a 3-week, double-blind, randomized, placebo-controlled study of acutely manic patients [5 ]. The improvement was maintained for an additional 9 weeks (a total of 12 weeks), with a 12.7 point drop in Young Mania Rating Scale score for lithium and a 14.5 point drop for aripiprazole. The most common adverse events with aripiprazole were headache, nausea, akathisia, sedation, and constipation and with lithium nausea, headache, constipation, and tremor. 

The effectiveness and cognitive effects of aripiprazole (mean dose 6.7 mg/day) have been assessed in a 6-week, open study in 23 children with attention-deficit/hyper-activity disorder [66 ]. There was overall significant improvement from baseline on attention-deficit/hyperactivity disorder and functional outcome measures. The most common adverse events were sedation (n = 18), headache (n = 11), nausea (n = 7), increased appetite (n = 6), musculoskeletal pain (n = 6), stomach ache (n = 5), hiccups (n = 4), and flu-like symptoms (n = 4). There was a significant increase in weight, with an increase from a mean of 37.6 kg at baseline to a mean of 39.6 kg at end of the study. 

Aripiprazole 5.25-15 mg IM (usually 9.75mg) 30 mg Less sedating antipsychotic Better than olanzapine if hypotensive IM - wait 2 h before repeat max 3 doses in 24 h... 

Four SGA long-acting injections are currently available risperidone microspheres, olanzapine pamoate, paliperidone palmitate and aripiprazole extended-release injection. The extended-release characteristics are achieved differently with each drug. A case analysis of clinical frials with olanzapine pamoate (2000-2008) reported an occurrence of postinjection delirium/sedation syndrome in approximately 0.07% of injections or 1.4% of patients [78 ]. A review of the published literature and clinical trial databases for olanzapine pamoate, risperidone microspheres and paliperidone palmitate found only one other case of postinjection delirium/sedation syndrome occurring in a patienf on placebo in a paliperidone palmitate trial. In four randomised, double-blind, placebo-controlled trials of paliperidone palmitate, the most common treatment-emergent adverse event was somnolence/sedation overall treatment discontinuation rates due to adverse events were similar to placebo. 

---